Literature DB >> 20197508

Prevalence of left ventricular regional dysfunction in arrhythmogenic right ventricular dysplasia: a tagged MRI study.

Aditya Jain1, Monda L Shehata, Matthias Stuber, Seth J Berkowitz, Hugh Calkins, João A C Lima, David A Bluemke, Harikrishna Tandri.   

Abstract

BACKGROUND: Although arrhythmogenic right ventricular dysplasia (ARVD) predominantly affects the right ventricle (RV), genetic/molecular and histological changes are biventricular. Regional left ventricular (LV) function has not been systematically studied in ARVD. METHODS AND
RESULTS: The study population included 21 patients with suspected ARVD who underwent evaluation with MRI including tagging. Eleven healthy volunteers served as control subjects. Peak systolic regional circumferential strain (Ecc, %) was calculated by harmonic phase from tagged MRI based on the 16-segment model. Patients who met ARVD Task Force criteria were classified as definite ARVD, whereas patients with a positive family history who had 1 additional minor criterion and patients without a family history with 1 major or 2 minor criteria were classified as probable ARVD. Of the 21 ARVD subjects, 11 had definite ARVD and 10 had probable ARVD. Compared with control subjects, probable ARVD patients had similar RV ejection fraction (58.9+/-6.2% versus 53.5+/-7.6%, P=0.20), but definite ARVD patients had significantly reduced RV ejection fraction (58.9+/-6.2% versus 45.2+/-6.0%, P=0.001). LV ejection fraction was similar in all 3 groups. Compared with control subjects, peak systolic Ecc was significantly less negative in 6 of 16 (37.5%) segments in definite ARVD and 3 of 16 segments (18.7%) in probable ARVD (all P<0.05).
CONCLUSIONS: ARVD is associated with regional LV dysfunction, which appears to parallel degree of RV dysfunction. Further large studies are needed to validate this finding and to better define implications of subclinical segmental LV dysfunction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197508      PMCID: PMC3036009          DOI: 10.1161/CIRCIMAGING.109.911313

Source DB:  PubMed          Journal:  Circ Cardiovasc Imaging        ISSN: 1941-9651            Impact factor:   7.792


  23 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Real-time imaging of two-dimensional cardiac strain using a harmonic phase magnetic resonance imaging (HARP-MRI) pulse sequence.

Authors:  Smita Sampath; J Andrew Derbyshire; Ergin Atalar; Nael F Osman; Jerry L Prince
Journal:  Magn Reson Med       Date:  2003-07       Impact factor: 4.668

3.  Regenerating MR tagged images using harmonic phase (HARP) methods.

Authors:  Nael F Osman; Jerry L Prince
Journal:  IEEE Trans Biomed Eng       Date:  2004-08       Impact factor: 4.538

4.  MR imaging of motion with spatial modulation of magnetization.

Authors:  L Axel; L Dougherty
Journal:  Radiology       Date:  1989-06       Impact factor: 11.105

Review 5.  Natural history and risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Jean-Sébastien Hulot; Xavier Jouven; Jean-Philippe Empana; Robert Frank; Guy Fontaine
Journal:  Circulation       Date:  2004-09-27       Impact factor: 29.690

6.  Left ventricular involvement in right ventricular dysplasia.

Authors:  B Pinamonti; G Sinagra; A Salvi; A Di Lenarda; T Morgera; F Silvestri; R Bussani; F Camerini
Journal:  Am Heart J       Date:  1992-03       Impact factor: 4.749

7.  Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.

Authors:  W J McKenna; G Thiene; A Nava; F Fontaliran; C Blomstrom-Lundqvist; G Fontaine; F Camerini
Journal:  Br Heart J       Date:  1994-03

8.  Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.

Authors:  Domenico Corrado; Loira Leoni; Mark S Link; Paolo Della Bella; Fiorenzo Gaita; Antonio Curnis; Jorge Uriarte Salerno; Diran Igidbashian; Antonio Raviele; Marcello Disertori; Gabriele Zanotto; Roberto Verlato; Giuseppe Vergara; Pietro Delise; Pietro Turrini; Cristina Basso; Franco Naccarella; Francesco Maddalena; N A Mark Estes; Gianfranco Buja; Gaetano Thiene
Journal:  Circulation       Date:  2003-11-24       Impact factor: 29.690

9.  Human heart: tagging with MR imaging--a method for noninvasive assessment of myocardial motion.

Authors:  E A Zerhouni; D M Parish; W J Rogers; A Yang; E P Shapiro
Journal:  Radiology       Date:  1988-10       Impact factor: 11.105

10.  Risk factors of cardiac arrest in arrhythmogenic right ventricular dysplasia.

Authors:  S Peters; G H Reil
Journal:  Eur Heart J       Date:  1995-01       Impact factor: 29.983

View more
  10 in total

1.  MR and CT imaging of Arrhythmogenic Cardiomyopathy.

Authors:  Harikrishna Tandri; Hugh Calkins
Journal:  Card Electrophysiol Clin       Date:  2011-06-01

Review 2.  Imaging phenotype vs genotype in nonhypertrophic heritable cardiomyopathies: dilated cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy.

Authors:  Subha V Raman; Cristina Basso; Harikrishna Tandri; Matthew R G Taylor
Journal:  Circ Cardiovasc Imaging       Date:  2010-11       Impact factor: 7.792

Review 3.  Arrhythmogenic ventricular cardiomyopathy: A paradigm shift from right to biventricular disease.

Authors:  Ardan M Saguner; Corinna Brunckhorst; Firat Duru
Journal:  World J Cardiol       Date:  2014-04-26

4.  Magnetic resonance imaging assessment of arrhythmogenic right ventricular cardiomyopathy/dysplasia in children.

Authors:  Shi-Joon Yoo; Lars Grosse-Wortmann; Robert M Hamilton
Journal:  Korean Circ J       Date:  2010-08-31       Impact factor: 3.243

5.  Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

Authors:  Deniz Akdis; Corinna Brunckhorst; Firat Duru; Ardan M Saguner
Journal:  Arrhythm Electrophysiol Rev       Date:  2016-08

6.  Left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy - a cardiac magnetic resonance imaging study.

Authors:  Soraya El Ghannudi; Anthony Nghiem; Philippe Germain; Mi-Young Jeung; Afshin Gangi; Catherine Roy
Journal:  Clin Med Insights Cardiol       Date:  2015-03-09

Review 7.  Science and practice of arrhythmogenic cardiomyopathy: A paradigm shift.

Authors:  Mohamed Elmaghawry; Federico Migliore; Nazar Mohammed; Despina Sanoudou; Mohammed Alhashemi
Journal:  Glob Cardiol Sci Pract       Date:  2013-11-01

Review 8.  Arrhythmogenic right ventricular cardiomyopathy (ARVC): cardiovascular magnetic resonance update.

Authors:  Anneline S J M te Riele; Harikrishna Tandri; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2014-07-20       Impact factor: 5.364

9.  Left Ventricular Involvement in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy Predicts Adverse Clinical Outcomes: A Cardiovascular Magnetic Resonance Feature Tracking Study.

Authors:  Meng-Ting Shen; Zhi-Gang Yang; Kai-Yue Diao; Li Jiang; Yi Zhang; Xi Liu; Yue Gao; Bi-Yue Hu; Shan Huang; Ying-Kun Guo
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

Review 10.  SCMR expert consensus statement for cardiovascular magnetic resonance of acquired and non-structural pediatric heart disease.

Authors:  Adam L Dorfman; Tal Geva; Margaret M Samyn; Gerald Greil; Rajesh Krishnamurthy; Daniel Messroghli; Pierluigi Festa; Aurelio Secinaro; Brian Soriano; Andrew Taylor; Michael D Taylor; René M Botnar; Wyman W Lai
Journal:  J Cardiovasc Magn Reson       Date:  2022-07-21       Impact factor: 6.903

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.